Table 1.
Baseline Demographicsa
| Characteristic | Participants With HIV N = 89 | Participants Without HIV N = 46 |
|---|---|---|
| Sex (%male) | 88 (78/89) | 100 (46/46) |
| Race | ||
| White (%) | 85 (76/89) | 89 (41/46) |
| Black (%) | 14 (12/89) | 7 (3/46) |
| Other (%) | 1 (1/89) | 4 (2/46) |
| BMI (kg/m2) | 27.5 ± 3.9 | 35.9 ± 5.6 |
| LDL-C (mg/dL) | 158 ± 27 | 120 ± 20 |
| Triglycerides (mg/dL) | 176 ± 99 | 143 ± 65 |
| Fasting glucose (mg/dL) | 95 ± 10 | 97 ± 9 |
| Hemoglobin A1c (%) | 5.4 ± 0.4 | 5.7 ± 0.3 |
| Framingham risk score (%) | 6.7 ± 5.1 | 8.4 ± 4.0 |
| Age (years) | 50.1 ± 7.5 | 53.0 ± 6.6 |
| Current smokingb (%) | 21 (18/84) | 15 (7/46) |
| Total cholesterol (mg/dL) | 241 ± 31 | 190 ± 24 |
| HDL-C (mg/dL) | 50 ± 14 | 42 ± 8 |
| Systolic BP (mmHg) | 123 ± 13 | 135 ± 16 |
| Current antihypertensive (%) | 24 (21/89) | 28 (13/46) |
| Log HIV-1 viral load (copies/mL) | 1.1 ± 0.2 | — |
| CD4 count (cells/mm3) | 682 ± 264 | — |
| Protease inhibitor-based therapy (%) | 25/89 (28) | — |
| NNRTI-based therapy (%) | 47/89 (53) | — |
| Integrase inhibitor-based therapy (%) | 3/89 (3) | — |
| Protease inhibitor and NNRTI (%) | 7/89 (8) | — |
| Integrase inhibitor and NNRTI (%) | 6/89 (7) | |
| NRTI only (%) | 1/89 (1) | — |
Abbreviations: BMI, body mass index; BP, blood pressure; CD4, cluster of differentiation 4; HDL-C, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor.
aNormally distributed data are reported as mean ± standard deviation.
bSmoking status was not reported for 5 participants with HIV.